Literature DB >> 28507404

Ceritinib for non-small cell lung cancer.

.   

Abstract

Entities:  

Keywords:  Zykadia (Novartis); ceritinib; non-small cell lung cancer

Year:  2017        PMID： 28507404      PMCID： PMC5407992          DOI： 10.18773/austprescr.2017.020

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  2 in total

1.  Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

Authors:  Lucio Crinò; Myung-Ju Ahn; Filippo De Marinis; Harry J M Groen; Heather Wakelee; Toyoaki Hida; Tony Mok; David Spigel; Enriqueta Felip; Makoto Nishio; Giorgio Scagliotti; Fabrice Branle; Chetachi Emeremni; Massimiliano Quadrigli; Jie Zhang; Alice T Shaw
Journal:  J Clin Oncol       Date:  2016-07-18       Impact factor: 44.544

2.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.